Coloplast A/S Announces Executive Changes, Effective 1 October 2020
August 18, 2020 at 06:02 am EDT
Share
Coloplast A/S announced that the Board of Directors have decided to expand the Executive Leadership Team from four members to six members as of 1 October 2020. The expansion aims to support the upcoming strategy which will focus on innovation and growth. A new Innovation Executive Vice President position position with responsibility for the company’s commercial offering and combining marketing, R&D and select global functions will be led by Nicolai Buhl Andersen. A new Growth Executive Vice President position position which combines the chronic care sales organization and the Wound & Skin care SBU will be led by Paul Marcun. Finally, HR is renamed People & Culture and elevated to the Executive leadership team to be led by Camilla G. Møhl. Nicolai Buhl Andersen is appointed Executive Vice President, Innovation and member of the Executive Leadership Team. Since joining Coloplast in 2005, Nicolai has held various senior management roles in the company including Head of Ostomy Care, Head of Sales, Nordic Region and Commercial Excellence. For the last 10 years, Nicolai has been SVP, Global Wound Care. Nicolai holds a Master's degree in Economics and Marketing from Copenhagen Business School and Sophia University, Japan. Camilla G. Møhl is appointed Senior Vice President, People & Culture and member of the Executive Leadership Team. Since joining Coloplast in 2016, Camilla has been VP, Global HR Commercial Organization and was promoted to VP Global HR in 2019. Prior to joining Coloplast, Camilla gained more than 15 years’ experience within HR at large international companies including Carlsberg and Mars. Camilla holds a Master’s degree in Human Resources Management from Copenhagen Business School.
Coloplast A/S specializes in the design, manufacturing, and marketing of disposable medical products. Net sales break down by family of products as follows:
- hygiene products (43.4%): urine bags, plugs, urinary testing systems and sets, etc.;
- ostomy care products (36.8%): bags and equipment used following intestinal operations;
- wound care and skincare products (11.9%): wound dressings, bandages, creams and gels;
- voice and respiratory care products (7.9%): voice prostheses for speaking, adhesives, laryngectomy cannulas for breathing, hands-free speaking devices, etc.
Net sales are distributed geographically as follows: Denmark (1.4%), the United States (21%), the United Kingdom (14%), France (10.8%) and other (52.8%).
COLOPLAST A/S 
